We are pleased to share the first patient has been dosed in our SAAVe Phase 1/2 #clinicaltrial of SP-101 + Augmenter, our investigational novel inhaled AAV #genetherapy for the treatment of #cysticfibrosis. Today's news marks a major milestone for us and the #CF patient community we seek to serve. Learn more: https://lnkd.in/eKrMvrRU
Spirovant Sciences, Inc.
生物技术研究
Philadelphia，Pennsylvania 2,438 位关注者
Gene therapy company developing cures for cystic fibrosis and other pulmonary diseases
关于我们
Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases. We are the only company advancing programs with both AAV and lentivirus vectors.
- 网站
-
https://www.spirovant.com
Spirovant Sciences, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Philadelphia，Pennsylvania
- 类型
- 私人持股
- 创立
- 2016
地点
-
主要
获取路线
3675 Market St
Suite 900
US，Pennsylvania，Philadelphia，19104
Spirovant Sciences, Inc.员工
动态
-
Discover more about our groundbreaking efforts in #genetherapy and #cysticfibrosis on Health Professional Radio’s recent podcast featuring CEO Joan L. #ICYMI Listen here: https://bit.ly/3HmPYnI ?
Spirovant Sciences - Potential of Gene Therapy in Targeting the Drivers of Cystic Fibrosis by Health Professional Radio - Podcast
podcasters.spotify.com
-
Recruiting Alert: Unfortunately, it has come to Spirovant’s attention that recruiting imposters including Jeremy Fuller have been running a LinkedIn page impersonating as a recruiter for Spirovant Sciences (and texting potential candidates details).?They are “recruiting” for an opening for a Remote Data Entry role, that does not exist. This person is NOT affiliated with Spirovant; there is no current opening for a remote data entry, customer services position, or any other position.?Do not share any personal or confidential information.?You may contact?[email protected] or [email protected] if you have further questions. All information about careers and open positions at Spirovant are only available on our website:?https://lnkd.in/dKfAK6q
-
Bringing novel therapeutics to patients requires a level of process overhaul and investment, especially for those who face a daily battle against #cysticfibrosis. CEO Joan L. shares how we are working to revolutionize treatments for cystic fibrosis with our investigational novel inhaled AAV #genetherapy, which may correct CFTR function and restore respiratory function. Learn more in Cell & Gene here: https://lnkd.in/eJpkvsFt
Tackling 3 Challenges In Developing An Inhaled Gene Therapy
cellandgene.com
-
The standard of care for people with #cysticfibrosis is in urgent need of an update, and a new inhaled #genetherapy approach may offer a solution. Read our own CEO Joan L.'s recent MedCity News article highlighting the crucial need for more investment in novel approaches like ours to address the pressing challenges facing CF patients. Read more below:
It’s time to build the infrastructure needed to scale up inhaled gene therapies targeting cystic fibrosis, and to bolster investment that supports several key program components. https://ow.ly/6ofY105694H
-